NEWS

  • GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS

    Thursday October 19, 7:25 pm ET Approvals Represent First Time a Regulatory Authority has Simultaneously Approved One Targeted Medicine for Five DisordersNow Approved for the Solid Tumor Cancer, Dermatofibrosarcoma ProtuberansUS Approval Also Granted for Treatment of Four Blood Diseases:Multiple Approvals in Only Five Years Highlight new Approach of Developing Treatments Based on Common Molecular Pathways… Read More »GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS

    READ MORE

    NOVARTIS DRUG

    Thursday, October 19, 2006 · Last updated 3:30 p.m. PTTHE ASSOCIATED PRESS WASHINGTON — A Novartis AG cancer drug has won expanded federal approval to treat five rare and potentially life-threatening diseases, the company said Thursday. Gleevec, also called imatinib mesylate, may now be prescribed to treat dermatofibrosarcoma protuberans tumors, as well as four blood… Read More »NOVARTIS DRUG

    READ MORE

    UIC RECEIVES $20 MILLION NCI GRANT TO RESEARCH BLOOD DISORDERS

    * Excerpts from UIC news release of September 6, 2006, announcing the NCI grant to the MPD International Research Consortium A $19.6 million National Cancer Institute grant has been awarded to the University of Illinois at Chicago College of Medicine to advance basic and clinical research for incurable blood disorders. It is the largest grant… Read More »UIC RECEIVES $20 MILLION NCI GRANT TO RESEARCH BLOOD DISORDERS

    READ MORE

    BIKE RIDE FUND-RAISER IN MEMORY OF BELMONT CYCLIST

    Thursday, July 20, 2006 Belmont resident Al Bolea lost his gallant seven-year fight against myelofibrosis at age 47. Bolea was a member of the Charles River Wheelmen (CRW) cycling club. Riding on his own, he dominated the hills on rides throughout Massachusetts and New England. Yet as a leader of CRW’s Wednesday night ride throughout… Read More »BIKE RIDE FUND-RAISER IN MEMORY OF BELMONT CYCLIST

    READ MORE

    AFTER DISCOVERING THE JAK2 MUTATION: NEXT STEPS IN DEVELOPING TARGETED TREATMENTS FOR PV, ET AND MF

    An interview with D. Gary Gilliland, PhD, MD Member, Medical Advisory Board, MPD FoundationProfessor of Medicine, Harvard Medical SchoolInvestigator, Howard Hughes Medical InstituteDirector, Leukemia Program, Dana-Farber/Harvard Cancer CenterDirector, Cancer Stem Cell Program, Harvard Stem Cell Institute . IntroductionPositive Identification of the Causal Gene MutationHow Gleevec WorksWhy the Mutation Doesn’t Always Show UpNext Steps in Drug… Read More »AFTER DISCOVERING THE JAK2 MUTATION: NEXT STEPS IN DEVELOPING TARGETED TREATMENTS FOR PV, ET AND MF

    READ MORE

    MPD GENE MUTATION DISCOVERED!

    After years of searching, a major breakthrough. The first news came out on March 17, 2005: A team of researchers at the Cambridge Institute for Medical Research, UK, led by Dr. Tony Green, announced that they had discovered a single point mutation in the JAK2 gene that appeared in 97% of polycythemia vera patients they… Read More »MPD GENE MUTATION DISCOVERED!

    READ MORE

    UIC JOINS FORCES WITH HARVARD, MAYO CLINIC TO BATTLE BONE MARROW DISORDERS

    By Sherri McGinnis Gonzalez 04/19/06 The Myeloproliferative Disorders Foundation awarded $750,000 to establish the MPD Research Alliance, a collaboration between UIC, Harvard Medical School and Mayo Clinic to accelerate drug development for incurable, progressive bone marrow disorders. The foundation plans to donate $10 million to the research alliance over the next five years to advance… Read More »UIC JOINS FORCES WITH HARVARD, MAYO CLINIC TO BATTLE BONE MARROW DISORDERS

    READ MORE

    MPD FOUNDATION FUNDS RESEARCH FOR INCURABLE BLOOD DISORDERS

    Medical Research NewsPublished: Tuesday, 11-Apr-2006 The Myeloproliferative Disorders Foundation has awarded $750,000 to establish the MPD Research Alliance, a collaboration of the University of Illinois at Chicago, Harvard Medical School and Mayo Clinic to accelerate drug development for incurable, progressive bone marrow disorders. The Foundation plans to donate $10 million to the Research Alliance over… Read More »MPD FOUNDATION FUNDS RESEARCH FOR INCURABLE BLOOD DISORDERS

    READ MORE

    I5 WEEKS AFTER HEALTH COLLAPSE, COACH BACK IN BELOVED ROUTINE

    Joe WilliamsSentinel Staff Writer March 19, 2006 EUSTIS — The sounds of baseball were all around Chet Lemon and it was music to his ears. The repeated thwack of metal-alloy bats striking baseballs during batting practice rang out. The chatter of coaches and players, working on bunt coverage and pickoff plays, filled the air. “I… Read More »I5 WEEKS AFTER HEALTH COLLAPSE, COACH BACK IN BELOVED ROUTINE

    READ MORE

    LETTER FROM THE PRESIDENT

    Summer, 2004 I can’t believe it’s been five years since we started the MPD Foundation. Lately I have been reflecting on all we have done since our inception: raising money, building a volunteer staff, funding scientific research, and building a nationwide and worldwide community of people with similar interests. The question in all of our… Read More »LETTER FROM THE PRESIDENT

    READ MORE

    1 35 36 37 38
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?